Although EGFR is overexpressed in over 90% of HNSCC cases, due to low EGFR mutation rates, acquired resistance, and the activation of alternative oncogenic pathways, its efficacy is insufficient [25]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.